Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.

1. The clinical use of the antitumour agent, doxorubicin, is largely limited by the development of a cumulative dose-related cardiotoxicity. This toxicity is generally believed to be caused by the formation of oxygen free radicals. In earlier studies it was established that flavonoids, naturally occ...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: van Acker, S. A., Kramer, K., Grimbergen, J. A., van den Berg, D. J., van der Vijgh, W. J., Bast, A.
Format: Artigo
Idioma:Inglês
Publicat: 1995
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1908788/
https://ncbi.nlm.nih.gov/pubmed/7582554
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars